Pro-inflammatory cytokines and mediators and their expression control

Pro-inflammatory cytokines and mediators represent a broad functional category of signaling molecules and the regulatory apparatus that governs their synthesis and secretion during an immune response [1: Dinarello, 2000]. This group includes key proteins such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which are primarily produced by activated macrophages and lymphocytes to coordinate systemic inflammation [2: Zhang & An, 2007]. The expression of these mediators is controlled by complex intracellular signaling cascades, most notably the NF-kappaB, MAPK, and JAK/STAT pathways, which serve as critical nodes for therapeutic intervention [3: Liu et al., 2017]. Dysregulation of this system is a primary driver of chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, as well as acute conditions like sepsis and cytokine release syndrome [4: Feldmann & Maini, 2003]. Pharmacological modulation of this system involves a multi-pronged approach: neutralizing monoclonal antibodies (e.g., infliximab), receptor antagonists (e.g., anakinra), and small-molecule inhibitors (e.g., tofacitinib) that suppress the transcriptional machinery responsible for cytokine production [5: Scott & Kingsley, 2006; 6: O'Shea et al., 2013].

Other names

Inflammatory cytokine cascadePro-inflammatory mediator expressionCytokine signaling pathwaysInflammatory mediators

Neutralization of pro-inflammatory cytokines, blockade of cytokine receptors, and inhibition of signaling pathways (e.g., JAK/STAT, NF-kappaB) to suppress mediator expression [5: Scott & Kingsley, 2006; 6: O'Shea et al., 2013].